PeptidesRx review

PeptidesRx is temporarily closed as of our October 23 website check. Its former catalog specified vial strength, volume and supply length, but current prices, clinicians, pharmacies and ordering are unverified. Treat the details below as a historical record; a return-to-service date has not been published.

Historical July 2026 catalog: PeptidesRx (PeptidesRx LLC, 1650 W Rosedale St, Suite 302, Fort Worth, Texas) is a telehealth platform selling prescription compounded peptides and GLP-1 medications from a single catalog. Its range spans GH secretagogues (sermorelin in injection, nasal spray and troche forms, sermorelin/ipamorelin, CJC-1295/ipamorelin, tesamorelin, GHRP-2, ibutamoren), recovery peptides (BPC-157, TB-500, KPV and their blends), longevity compounds (GHK-Cu, epitalon, MOTS-C, thymosin alpha-1, ARA-290, methylene blue, sirolimus), neuro items (NAD⁺, semax and selank), sexual health (PT-141, oxytocin), testosterone cypionate and gonadorelin, brand growth hormone, and compounded semaglutide, tirzepatide and retatrutide. It positions itself explicitly as a compliance-first alternative to gray-market research-chemical sellers.

Historical July 2026 catalog: Video-gated and subscription-shaped. You enroll, meet a licensed provider by video for a good-faith exam, and a prescription — if issued — goes to a compounding pharmacy for shipping, with one good-faith exam stated to cover every item in your protocol cart. Two structural claims stand out and are worth crediting. It states its providers are board-certified nurse practitioners and physicians who are W-2 employees of its medical group rather than independent contractors, which is a real accountability argument almost nobody in this category makes. And it advertises PCAB-accredited compounding pharmacies; PCAB accreditation is a genuine third-party standard beyond state licensure. Two claims cut the other way. The site advertises meeting a provider "in as little as 30 seconds", which is difficult to reconcile with a meaningful good-faith exam for injectable prescriptions and deserves a hard look. And product pages don't say which pharmacy makes your vial, so ask before you order. No individual clinician, medical director or state list is published either.

Historical July 2026 catalog: Unusually well-specified pricing, and easy to misread. Every item is priced "per supply" with the supply defined: sermorelin from $55 for 3 mg in a 3 mL vial at 1 mg/mL described as roughly fifteen days, $80 for 15 mg in a 5 mL vial at 3 mg/mL described as roughly fifty days, $77 for a 30 mL nasal spray described as roughly a hundred days, $75 for thirty 600 mcg troches. CJC-1295/ipamorelin is $100 for a 5 mL vial at 2 mg/2 mg per mL. BPC-157 with TB-500 is $100 for a five-week supply. NAD⁺ runs $80 for 1,000 mg in a 10 mL vial at 100 mg/mL, up to $160 for 2,000 mg at 200 mg/mL. Testosterone cypionate is $59 for a 10 mL vial at 200 mg/mL described as a monthly supply. Now the trap: the cart states a monthly total that renews automatically, so a vial the catalog calls a fifty-day supply is charged every thirty days. So the per-supply figures are not monthly prices, and there is no single monthly price to plan around. Ask precisely what cadence you will be billed on and whether the shipment interval matches the supply length.

Historical July 2026 catalog: Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The site states that all prescriptions come from licensed US providers, that medication is compounded by licensed US pharmacies pursuant to a valid prescription, and — in its own footer — that compounded medications are not FDA-approved drug products, which is the correct disclosure. Compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, this catalog is a masterclass in why a price list is not a recommendation. Sermorelin, CJC-1295/ipamorelin and tesamorelin act on the growth-hormone axis; tesamorelin is an approved drug for HIV-associated lipodystrophy specifically, and the others have real mechanisms with thin long-term outcome data. BPC-157, TB-500, GHK-Cu, epitalon, MOTS-C and thymosin alpha-1 have essentially no controlled human outcome trials. Injected NAD⁺ has none; oral NR and NMN raise a biomarker. PT-141 is approved for one narrow indication in premenopausal women, so prescribing it to anyone else is off-label use. Testosterone cypionate is an approved molecule requiring ongoing hematocrit, PSA and testosterone monitoring. A catalog this wide will always be wider than the evidence. Individual results vary.